Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study

被引：0
|
作者：
Gasiorek, A. [1 ]
Heydorn, A. [1 ]
Kirkeby, K. [1 ]
Key, C. [2 ]
Toubro, S. [1 ]
Schefe, L. H. [1 ]
Dahl, K. [1 ]
Hjerpsted, J. B. [1 ]
Vegge, A. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
[2] ICON Plc, San Antonio Clin Res Unit, San Antonio, TX USA
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
74
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [41] Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
    Handelsman, Yehuda
    Wyne, Kathleen
    Cannon, Anthony
    Shannon, Michael
    Schneider, Doron
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (09): : S14 - S29
  • [42] A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy
    Knop, Filip K.
    Urva, Shweta
    Rettiganti, Mallikarjuna
    Benson, Charles T.
    Roell, William C.
    Mather, Kieren J.
    Haupt, Axel
    Pratt, Edward John
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5474 - 5478
  • [43] A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
    Tillner, Joachim
    Posch, Maximilian G.
    Wagner, Frank
    Teichert, Lenore
    Hijazi, Youssef
    Einig, Christine
    Keil, Stefanie
    Haack, Torsten
    Wagner, Michael
    Bossart, Martin
    Larsen, Philip J.
    DIABETES OBESITY & METABOLISM, 2019, 21 (01): : 120 - 128
  • [44] Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
    Zaffina, Isabella
    Pelle, Maria Chiara
    Armentaro, Giuseppe
    Giofre, Federica
    Cassano, Velia
    Sciacqua, Angela
    Arturi, Franco
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [45] Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program
    Peng, Hui
    Want, Laura L.
    Aroda, Vanita R.
    CURRENT DIABETES REPORTS, 2016, 16 (05)
  • [46] Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program
    Hui Peng
    Laura L. Want
    Vanita R. Aroda
    Current Diabetes Reports, 2016, 16
  • [47] Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis
    Marjan Gharagozloo
    Matthew D. Smith
    Elias S. Sotirchos
    Jing Jin
    Keya Meyers
    Michelle Taylor
    Thomas Garton
    Riley Bannon
    Hannah-Noelle Lord
    Ted M. Dawson
    Valina L. Dawson
    Seulki Lee
    Peter A. Calabresi
    Neurotherapeutics, 2021, 18 : 1834 - 1848
  • [48] Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis
    Gharagozloo, Marjan
    Smith, Matthew D.
    Sotirchos, Elias S.
    Jin, Jing
    Meyers, Keya
    Taylor, Michelle
    Garton, Thomas
    Bannon, Riley
    Lord, Hannah-Noelle
    Dawson, Ted M.
    Dawson, Valina L.
    Lee, Seulki
    Calabresi, Peter A.
    NEUROTHERAPEUTICS, 2021, 18 (03) : 1834 - 1848
  • [49] Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis
    Gharagozloo, M.
    Smith, M.
    Sotirchos, E.
    Jin, J.
    Meyers, K.
    Taylor, M.
    Lord, H.
    Garton, T.
    Dawson, T.
    Dawson, V.
    Lee, S.
    Calabresi, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 61 - 62
  • [50] Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity
    Nathan, B. M.
    Rudser, K. D.
    Abuzzahab, M. J.
    Fox, C. K.
    Coombes, B. J.
    Bomberg, E. M.
    Kelly, A. S.
    CLINICAL OBESITY, 2016, 6 (01) : 73 - 78
12345